Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis

Te Sheng Chang; Yu Chih Wu; Shui Yi Tung; Kuo Liang Wei; Yung Yu Hsieh; Hao Chun Huang; Wei Ming Chen; Chien Heng Shen; Chang Hsien Lu; Cheng Shyong Wu; Ying Huang Tsai; Yen Hua Huang

doi:10.1038/ajg.2015.100

Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis

Te Sheng Chang, Yu Chih Wu, Shui Yi Tung, Kuo Liang Wei, Yung Yu Hsieh, Hao Chun Huang, Wei Ming Chen, Chien Heng Shen, Chang Hsien Lu, Cheng Shyong Wu, Ying Huang Tsai, Yen Hua Huang

Research output: Contribution to journal › Article › peer-review

60 Citations (Scopus)

Abstract

Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC), and all liver study societies recommend HCC surveillance in patients with cirrhosis. However, no ideal modality for HCC surveillance has been determined. The aim of this study is to assess the effectiveness of α-fetoprotein (AFP) measurement in HCC surveillance.METHODS:In this retrospective analysis, all patients with cirrhosis, who received HCC surveillance through ultrasound (US) and AFP measurement between January 2002 and July 2010, were followed up until June 2013. The performance effectiveness of surveillance using AFP, US, or both in HCC detection was compared.RESULTS:Overall, 1,597 patients were followed for a median duration of 4.75 (range 1.42-12) years. Over the 8563.25-person-year follow-up period, 363 patients (22.7%) developed HCCs. For HCC detection, the area under the receiver operator characteristic curve of surveillance AFP was 0.844 (95% confidence interval: 0.820-0.868, P

Original language	English
Pages (from-to)	836-844
Number of pages	9
Journal	American Journal of Gastroenterology
Volume	110
Issue number	6
DOIs	https://doi.org/10.1038/ajg.2015.100
Publication status	Published - Jun 10 2015

ASJC Scopus subject areas

Gastroenterology
Medicine(all)

Access to Document

10.1038/ajg.2015.100

Fingerprint Dive into the research topics of 'Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis'. Together they form a unique fingerprint.

Cite this

Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. / Chang, Te Sheng; Wu, Yu Chih; Tung, Shui Yi; Wei, Kuo Liang; Hsieh, Yung Yu; Huang, Hao Chun; Chen, Wei Ming; Shen, Chien Heng; Lu, Chang Hsien; Wu, Cheng Shyong; Tsai, Ying Huang; Huang, Yen Hua.

In: American Journal of Gastroenterology, Vol. 110, No. 6, 10.06.2015, p. 836-844.

Research output: Contribution to journal › Article › peer-review

Chang, Te Sheng ; Wu, Yu Chih ; Tung, Shui Yi ; Wei, Kuo Liang ; Hsieh, Yung Yu ; Huang, Hao Chun ; Chen, Wei Ming ; Shen, Chien Heng ; Lu, Chang Hsien ; Wu, Cheng Shyong ; Tsai, Ying Huang ; Huang, Yen Hua. / Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. In: American Journal of Gastroenterology. 2015 ; Vol. 110, No. 6. pp. 836-844.

@article{453bffa4dd96463985ac0e99b142fc90,

title = "Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis",

abstract = "Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC), and all liver study societies recommend HCC surveillance in patients with cirrhosis. However, no ideal modality for HCC surveillance has been determined. The aim of this study is to assess the effectiveness of α-fetoprotein (AFP) measurement in HCC surveillance.METHODS:In this retrospective analysis, all patients with cirrhosis, who received HCC surveillance through ultrasound (US) and AFP measurement between January 2002 and July 2010, were followed up until June 2013. The performance effectiveness of surveillance using AFP, US, or both in HCC detection was compared.RESULTS:Overall, 1,597 patients were followed for a median duration of 4.75 (range 1.42-12) years. Over the 8563.25-person-year follow-up period, 363 patients (22.7%) developed HCCs. For HCC detection, the area under the receiver operator characteristic curve of surveillance AFP was 0.844 (95% confidence interval: 0.820-0.868, P",

author = "Chang, {Te Sheng} and Wu, {Yu Chih} and Tung, {Shui Yi} and Wei, {Kuo Liang} and Hsieh, {Yung Yu} and Huang, {Hao Chun} and Chen, {Wei Ming} and Shen, {Chien Heng} and Lu, {Chang Hsien} and Wu, {Cheng Shyong} and Tsai, {Ying Huang} and Huang, {Yen Hua}",

year = "2015",

month = jun,

day = "10",

doi = "10.1038/ajg.2015.100",

language = "English",

volume = "110",

pages = "836--844",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis

AU - Chang, Te Sheng

AU - Wu, Yu Chih

AU - Tung, Shui Yi

AU - Wei, Kuo Liang

AU - Hsieh, Yung Yu

AU - Huang, Hao Chun

AU - Chen, Wei Ming

AU - Shen, Chien Heng

AU - Lu, Chang Hsien

AU - Wu, Cheng Shyong

AU - Tsai, Ying Huang

AU - Huang, Yen Hua

PY - 2015/6/10

Y1 - 2015/6/10

N2 - Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC), and all liver study societies recommend HCC surveillance in patients with cirrhosis. However, no ideal modality for HCC surveillance has been determined. The aim of this study is to assess the effectiveness of α-fetoprotein (AFP) measurement in HCC surveillance.METHODS:In this retrospective analysis, all patients with cirrhosis, who received HCC surveillance through ultrasound (US) and AFP measurement between January 2002 and July 2010, were followed up until June 2013. The performance effectiveness of surveillance using AFP, US, or both in HCC detection was compared.RESULTS:Overall, 1,597 patients were followed for a median duration of 4.75 (range 1.42-12) years. Over the 8563.25-person-year follow-up period, 363 patients (22.7%) developed HCCs. For HCC detection, the area under the receiver operator characteristic curve of surveillance AFP was 0.844 (95% confidence interval: 0.820-0.868, P

AB - Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC), and all liver study societies recommend HCC surveillance in patients with cirrhosis. However, no ideal modality for HCC surveillance has been determined. The aim of this study is to assess the effectiveness of α-fetoprotein (AFP) measurement in HCC surveillance.METHODS:In this retrospective analysis, all patients with cirrhosis, who received HCC surveillance through ultrasound (US) and AFP measurement between January 2002 and July 2010, were followed up until June 2013. The performance effectiveness of surveillance using AFP, US, or both in HCC detection was compared.RESULTS:Overall, 1,597 patients were followed for a median duration of 4.75 (range 1.42-12) years. Over the 8563.25-person-year follow-up period, 363 patients (22.7%) developed HCCs. For HCC detection, the area under the receiver operator characteristic curve of surveillance AFP was 0.844 (95% confidence interval: 0.820-0.868, P

UR - http://www.scopus.com/inward/record.url?scp=84930758143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930758143&partnerID=8YFLogxK

U2 - 10.1038/ajg.2015.100

DO - 10.1038/ajg.2015.100

M3 - Article

C2 - 25869392

AN - SCOPUS:84930758143

VL - 110

SP - 836

EP - 844

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -

Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this